妊娠期哮喘的现代管理
该综述指出哮喘影响8%至13%的妊娠,未控制哮喘较控制者与早产、妊娠期高血压疾病及胎儿生长受限或小于胎龄儿风险升高相关;文章整合生物通路、表型与内型原则及妊娠期免疫变化,强调主动监测与阶梯治疗以维持控制。
要点
- 未控制哮喘是妊娠风险的主要驱动因素,而非哮喘诊断本身。
- 未控制哮喘与早产、妊娠期高血压疾病及胎儿生长受限或小于胎龄儿风险升高相关。
- 强调主动监测症状与客观指标,维持或升级控制药物治疗以实现症状完全缓解。
核心结论
- 未控制哮喘是妊娠不良结局的主要驱动因素,维持哮喘控制以实现症状完全缓解有助于优化母胎结局。
研究设计与样本
- 综述,纳入妊娠期哮喘相关文献,整合生物通路、表型与内型原则及妊娠期免疫变化。
主要发现
- 哮喘影响8%至13%的妊娠,未控制哮喘较控制者与早产(校正比值比:1.3 vs 1.6)、妊娠期高血压疾病(校正比值比:1.2 vs 1.5)及胎儿生长受限或小于胎龄儿(校正比值比:1.2 vs 1.4)风险升高相关。
关键数值与推荐
- 强调主动监测、常规评估症状与客观指标,并维持或升级(step-up)控制药物治疗以在整个妊娠期维持控制。
- 综述了抗炎缓解治疗及维持加缓解治疗等现代策略,并强调非药物干预。
临床怎么用
- 对妊娠期哮喘应主动监测症状与客观指标,维持或升级控制药物以维持控制,并关注病毒感染、空气污染、肥胖、过敏性鼻炎、胃食管反流及阻塞性睡眠呼吸暂停等可干预因素。
局限性
- 本文为综述,未报告原始研究样本量、置信区间或P值等具体统计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma affects 8% to 13% of pregnancies and is associated with adverse maternal and fetal outcomes. The evidence consistently demonstrates that uncontrolled asthma in pregnancy is the primary driver of this pregnancy risk rather than the diagnosis alone. Compared with controlled disease, uncontrolled asthma has been associated with higher rates of preterm birth (adjusted odds ratio: 1.3 vs 1.6), hypertensive disorders of pregnancy (adjusted odds ratio: 1.2 vs 1.5), and impaired fetal growth or small-for-gestational-age neonates (adjusted odds ratio: 1.2 vs 1.4). This paper aimed to review the biologic pathways linking active asthma to adverse pregnancy outcomes, including airway inflammation, oxidative stress, placental dysfunction, and maternal hypoxemia. Building on modern understanding of asthma heterogeneity, this review integrates phenotype- and endotype-informed principles with pregnancy-specific immunologic shifts, highlighting how a Th2-predominant state may exacerbate disease activity and modify risk in susceptible patients. Multiple modifiable contributors, including viral infections, air pollution, indoor exposures, obesity, allergic rhinitis, gastroesophageal reflux disease, and obstructive sleep apnea, further influence disease activity and underscore the importance of active management. This study synthesizes updated, practical guidance aligned with international asthma guidelines emphasizing proactive monitoring, routine assessment of symptoms and objective measures, and continuation or escalation ("step-up") of controller therapy to maintain control throughout pregnancy. In addition, this study reviewed contemporary strategies for asthma management, including anti-inflammatory reliever therapy and maintenance and reliever therapy, and highlighted nonpharmacologic interventions. Across this review, the emphasis lies on the importance of asthma control, with a goal of complete remission of symptoms, to optimize maternal-fetal outcomes. This study highlights areas of future research, including the implementation of precision-guided asthma care in pregnancy and the use of biologic therapies to prevent active disease.
引用
- Meislin R, Bianco A, Wang JG, et al. Asthma in pregnancy: contemporary management. Am J Obstet Gynecol. 2026. PMID: 41833702. doi:10.1016/j.ajog.2026.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。